Vapotherm are a global medical technology company focused on the development and promotion of our proprietary High Velocity Therapy products that are used to treat patients of all ages suffering from respiratory distress. In the UK and Ireland, our technology is present across several different care areas within the NHS and HSE. We provide clinical and product expertise, backed-up by an efficient administration and service department based in Edinburgh.
Our High Velocity Therapy delivers non-invasive ventilatory support by providing heated, humidified, and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Our Precision Flow and HVT 2.0 systems, which use high velocity therapy, are clinically validated alternatives to, and address many limitations of, the current standard of care for the treatment of respiratory distress, including patient transfer and ambulation, in a hospital setting.
Vapotherm high velocity therapy is more than oxygen therapy. It is a fast and safe way to provide treatment for undifferentiated respiratory distress with one single tool for patient populations from premature neonates to hypercapnic COPD patients. Trusted and available in more than 40 countries, our technology has treated more than 2.5 million patients and we have a global installed base of over 25,000 capital units.